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Abstract 
We developed an efficient strategy, “Combinatorial Strategy”, for cloning different vectors with various 
clone sites. 1) Using originally existed clone sites from circular vectors to prepare the inserts, and if no 
appropriate sites available, performing SDM to create compatible sites, to achieve maximal correct digestion 
of the inserts. 2) Different vectors were digested with various restriction endonucleases, and then 
dephosphorylated with CIP. 3) Top10 competent cells were used for transformation to increase the 
transformant colonies. Our results showed that, when blunt sites, or a Xba I site was adopted for ligation, the 
percentages of positive clones were about 50%. Whereas, when different sites, including one blunt and 
another Pst I sites, Not I and Xho I sites, the percentages of positive clones were nearly 100%. Using this 
strategy, most vectors could be successfully cloned through “one ligation, one transformation, three to five 
minipreps”. 
 
Key words: Quantitative models, Cloning vectors, Calf intestinal phosphatase (CIP) treatment, 
Site-directed mutagenesis (SDM), Combinatorial strategy, Top10, DNA recombination. 
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Introduction 
 
The successful production and intracellular replication of recombinant DNA were first reported in 1972 and 
1973
1, 2
, and these techniques have significantly revolutionized biological sciences in the past decades. At the 
genome era, more and more gene sequences of a growing number of species become available, and many 
different vector systems have been developed by scientists. Therefore, there is an increasing need for 
efficient strategies to clone interested genes, precisely and efficiently, into various expression vectors 
according to specific aims. For example, to establish stable transgene cell lines, lentiviral vectors (LVs) 
might be a good choice, and to achieve conditional transgenesis and gene knockdown, drug-inducible 
systems were designed for these purposes
3-12
. 
Generally, the DNA recombination techniques were of low efficiency and randomness. To overcome the 
randomness of vector cloning with certainty, recently, we reported an efficient cloning method, 
“Combinatorial strategy”, for lentiviral vectors using site-directed mutagenesis (SDM) to insert clone site 
BamH I
13
. SDM was first established at 1978 by Hutchison et al., and it is essential in gene functional 
studying, genetic engineering, protein engineering, and vector modifications
14-16
. Currently, the 
QuikChange
TM
 SDM System developed by Stratagene is a commonly used kit for mutagenesis using plasmid 
double-stranded DNA as templates. The advantage of this strategy is that the products after mutagenesis are 
circular, double-stranded plasmid DNA. As results, theoretically, 100% of the linearized DNA fragments are 
with correct-cleaved ends. Therefore, maximal efficiencies of ligation could be achieved
13
.  
In our neuroscience lab focused on Parkinson disease, we need to clone several different kinds of expression 
vectors for α-synuclein (α-Syn) and related genes, such as Rab3A, GDI, β5, Plk217, etc., both wild type (WT) 
and mutants, to investigate their functional relations in vitro and in vivo. The aim of this study is to generalize 
our reported combinatorial strategy to efficiently construct different expression vectors with various clone 
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sites, such as blunt-end sites (Swa I, Pme I and EcoR V), one blunt-end and one-overhang-end sites (Pme I 
and Pst I), two different overhang-end sites (Not I and Xho I), and one overhang-end site (Xba I), etc.. 
Encouraged by our former report
13
, with our optimized method, we successfully constructed 18 different 
vectors, mostly through “one ligation, one transformation, and a few minipreps”, for each of them. The 
percentages of positive clones with blunt sites, different clone sites, and a Xba I site, were approximately 47% 
± 31% (n=13), 93% ± 12% (n=3), and 36% ± 10% (n=2), respectively. This study provided important 
quantitative models for efficient construction of different vectors, and laid the significant foundations for 
gene functional analyses. 
 
Results 
 
Pst I and Xba I insertion by SDM 
SDM was performed by PCR, and the parental template DNA was digested with Dpn I. Different annealing 
temperatures were used for pcDNA4/β5WT/3’-Pst I, pcDNA4/β5T1A/3’-Pst I, pcDNA4/β5TW/5’-Xba I, 
pcDNA4/β5T1A/5’-Xba I, and pcDNA4/β5T1A/5’-Xba I/3’-Xba I insertions, representing approximately 
Tm
*
-9°C, Tm
 
+ 3°C, and Tm
*
-5°C (Table 1 and 2; Figure 2 and 3), respectively. After transformation into 
Top10 or DH5α cells and identified by sequencing, our results showed that, the mutagenesis efficiencies were 
approximately 50% for pcDNA4/β5WT/3’-Pst I insertion, 33.3% for pcDNA4/β5T1A/3’-Pst I insertion, 10% 
for pcDNA4/β5T1A/5’-Xba I insertion, and 50% for pcDNA4/β5T1A/5’-Xba I/3’-Xba I insertion, 
respectively. In contrast, positive mutagenesis clones were not obtained for pcDNA4/β5WT/5’-Xba I 
insertion after sequencing 18 minipreps (Table 1 and 2). These data demonstrated that the majority of our 
designed mutagenesis was successfully achieved. 
 
Efficient cloning of different vectors with various clone sites 
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Construction of LVs with blunt-end clone sites 
 
A blunt-end clone site Swa I of pWPI/Neo LV was employed as clone site. To protect the vector 
self-circularization, we removed the 5’-phosphate groups of the vector DNA with calf intestinal phosphatase 
(CIP) treatment following Swa I digestion. This treatment could diminish the background of transformed 
colonies that carried empty plasmids. At the same time, the colony number would be significantly decreased 
after transformation
18-20
. Insert (α-Syn WT and A30P, A53T mutants; Rab3A WT and T36N, Q81L mutants; 
GDI WT and R218E, R240A mutants; β5 WT and T1A mutant; respectively) and vector were pooled 
together in 10µl ligation reactions with DNA concentrations around 18.9~42ng/µl, and insert to vector molar 
ratios about 1~3.4:1 (Table 3, Figure 1). To improve the transformation efficiencies, Top10 cells were used 
as hosts, and 2 to about 20 colonies were obtained after transformation. After identification by restriction 
endonulease digestion and sequencing, the percentages of positive clones with monomeric, correct-oriented 
inserts were ranging from 20% to 100%, respectively (Table 3). All the blunt-end cloning described above 
was achieved by performing one ligation and one transformation, except the cloning of pWPI/GDIWT/Neo. 
15 colonies were resulted from the first ligation and transformation, and after identification with BamH I 
digestion, 9 clones were with opposite-directed inserts, and the other 6 clones were with unknown DNAs. 
Through the second ligation and transformation, positive clones of pWPI/GDIWT/Neo were obtained (Table 
3). 
 
To construct inducible LVs, pLenti CMV/TO Puro DEST was digested with EcoR V, and followed by CIP 
treatment. In 10µl ligation system, the molar ratios of insert β5 WT and T1A mutant to pLenti vector were 
22:1 and 14.1:1, and the DNA amounts were about 18.9ng/µl and 14ng/µl, respectively (Table 3, Figure 1). 
After transformation into Top10 cells, 12 and 13 colonies were obtained, and the percentages of positive 
clones were 37.5% and 12.5%, respectively. Taken together, the percentages of inserted clones and positive 
clones with blunt-end ligations, were approximately 77% ± 25%, and 47% ± 31%, respectively (Table 3, 
Figure 4). 
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Construction of different vectors with various clone sites 
 
pLVCT-tTR-KRAB was first digested with Pme I, then with Pst I, sequentially, and then treated with CIP. In 
10µl ligation system, the molar ratios of inserts β5WT and T1A mutant to pLVCT vector were 3:1, and the 
DNA amounts were 17.6ng/µl, respectively (Table 3, Figure 2). After transformation into Top10 cells, about 
100 and 300 colonies were obtained. After identification, all the recombinant clones were with correct 
directions, therefore, the percentages of inserted clones and positive clones were both 80% and 100%, 
respectively (Table 3).  
Due to the failure to insert 5’-Xba I site for pcDNA4/β5WT (Table 2), pcDNA4/β5T1A/5’-Xba I/3’-Xba I 
was digested with Not I and Xho I, simultaneously, and followed by CIP treatment, the insert β5WT 
(digested with Not I and Xho I) was ligated into the vector pcDNA4/5’-Xba I/3’-Xba I to form 
pcDNA4/β5WT/5’-Xba I/3’-Xba I (Figure 3). The molar ratio of insert β5WT to pcDNA4/5’-Xba I/3’-Xba I 
vector was 1.9:1, and the DNA amount was 28.1ng/µl, respectively. After transformation into Top10 cells, 
about 500 colonies were obtained, the percentages of inserted clones and positive clones were both 100% 
(Table 3). 
 
Construction of inducible pTet/β5WT andpTet/β5T1A vectors with a Xba I clone site 
 
Previously, we reported the construction of pWPI/hPlk2 WT and mutant vectors with a BamH I site by 
inserting BamH I clone site at the 3’-ends of hPlk213. The pTetO-HGMoPrP vector was digested with Xba I 
to cut off the insert HGMoPrP, followed by CIP treatment. β5WT and β5T1A inserts were cleaved from 
vectors pcDNA4/5’-Xba I/3’-Xba I, and ligated with pTet by Xba I clone site, to form inducible vector 
pTet/β5WT and pTet/β5T1A (Figure 3). In 10µl ligation system, the molar ratios of insert β5WT and T1A 
mutant to pTet vector were 2.1:1 and 1.5:1, and the DNA amounts were 21.9ng/µl and 19.7ng/µl, 
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respectively. After transformation into Top10 cells, about 1000 colonies of each were obtained. The 
percentages of inserted clones were 100% for both of them, and those of positive clones were 28.6% and 
42.9%, respectively (Table 3). 
Taken together, the percentages of inserted clones and positive clones with ligation of blunt-end sites 
(including Swa I, Pme I and EcoR V), different clone sites (EcoR V, Pme I and Pst I; Not I and Xho I), and a 
Xba I site (Figure 1, 2 and 3), were approximately 77% ± 25% and 47% ± 31% (n=13), both 93% ± 12% 
(n=3), and 100% ± 0 and 36% ± 10% (n=2) of identified clones, respectively. Among them, the efficiencies 
of blunt-end cloning and Xba I site cloning were not significantly different (47% ± 31% vs 36% ± 10%, 
P>0.05), these data were similar with our previous report with a BamH I clone site
13
 (Table 3). In contrast, 
the efficiencies between blunt-end cloning and different site cloning (47% ± 31% vs 93% ± 12%), different 
site cloning and Xba I site cloning (93% ± 12% vs 36% ± 10%) were significantly different (P<0.05). 
 
Discussion 
 
Creation of compatible clone sites between vectors and inserts is the first step for successful cloning, and it is 
critical that the cutting-ends of DNA fragments are correctly generated after restriction digestion, particularly 
for large-size, low-efficiency cloning. Generally, LVs carry limited clone sites, and a unique clone site 
usually used for cloning, such as BamH I or EcoR V
7, 13, 21
 etc. Therefore, it is necessary to create compatible 
clone sites between the vectors and inserts. SDM is a powerful tool to change DNA sequences at specific 
positions in genetic engineering, including insertion of clone sites
15, 16, 22
. According to the working format of 
the QuikChange
TM
 SDM System, double-stranded plasmid DNA was used as templates, therefore, after Dpn I 
digestion and transformation, the mutagenesis products are circular double-stranded plasmid DNA 
(Stratagene). As a result, after restriction digestion, 100% of the purified linearized DNA fragments through 
Agarose Gel Electrophoresis were theoretically with correct ends. Whereas, the correct cutting ends could 
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not be confirmed with the method of incorporating of restriction sites into PCR primers
23, 24
. In this study, Pst 
I clone site at the 3’-ends of β5 WT and T1A mutant genes was inserted by SDM, to achieve the cloning with 
5’-blunt end and 3’-Pst I end between pLVCT vector and β5 WT and T1A mutant inserts. Our data 
demonstrated that the clone efficiencies were significantly improved with this strategy. The percentages of 
positive clones with monomeric, correct-oriented inserts were 80% for pLVCT/β5WT, and 100% for 
pLVCT/β5T1A, respectively (Table 3, Figure 2). In addition, Xba I site was also inserted at both 5’- and 3’- 
ends of β5T1A mutant, and Tet-inducible expression vectors, pTet/β5WT and pTet/β5T1A, were constructed 
with a Xba I site between pTet vector and β5 WT and T1A mutant inserts. The percentages of positive clones 
were 28.6% and 42.9% (36% ± 10%, n=2), respectively (Table 3, Figure 3). These data were consistent with 
our former report
13
. 
Ligation and transformation are complicated procedures, and many factors could affect their efficiencies, 
such as the dephosphorylation of the vectors, the concentrations and ratios of the vector and insert DNA, the 
amount of DNA used for transformation, and so on. Removing the 5’-phosphate residues from both termini 
of the vector DNA can efficiently minimize the re-circularization of vector DNA, and therefore, decrease the 
background with empty transformants. At the same time, the transformation colonies were significantly 
decreased, particularly for ligation with blunt ends, because the ligation efficiency of blunt ends was much 
lower than cohesive end ligation
25, 26
. Our data also demonstrated this phenomenon (Table 3). In our 
experiment, the transformant number of blunt-end ligations was from 2 to 20, whereas, the transformation 
colonies of the ligation with one blunt end and one cohesive end were about 100 and 300, respectively. In 
addition, about 500 colonies were obtained when Not I and Xho I sites were used for ligation, and about 1000 
colonies were resulted from Xba I site ligation (Table 3). Furthermore, the ligation efficiencies were 
significantly affected by vector sizes. For instance, when pLVCT (12kb), pcDNA4 (5.1kb), and pTet (3.2kb) 
were used for ligation with β5 WT and T1A mutant inserts, more transformation colonies were obtained with 
the decrease of vector sizes (Table 3). To investigate the effects of the molar ratios of insert to vector on the 
transformant number and the percentages of positive clones, a large range of molar ratios, from 1.7 to 22:1, 
was used for ligation with blunt ends, there was no significant different between the number of obtained 
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transformants and the percentages of positive clones (Table 3). Taken together, the percentages of positive 
clones with the ligation of blunt ends, different clone sites, and a Xba I, were approximately 47% ± 31% 
(n=13), 93% ± 12% (n=3), and 36% ± 10% (n=2) of identified clones, respectively. The efficiencies of 
blunt-end cloning and Xba I site cloning were not significantly different (47% ± 31% vs 36% ± 10%, 
P>0.05), In contrast, the efficiencies between blunt-end cloning and different site cloning (47% ± 31% vs 93% 
± 12%), different site cloning and Xba I site cloning (93% ± 12% vs 36% ± 10%) were significantly different 
(P<0.05). The data of Xba I cloning were consistent with our previous report with BamH I site cloning 
(Table 3)
13
. 
Here, we reported quantitative models for efficient construction of different vectors, which included different 
sizes of vectors and inserts, and various clone sites. Firstly, creating clone sites by SDM, or taking advantage 
of originally existed clone sites of circular vectors, could guarantee that 100% of the linearized DNA 
fragments were with correct cutting-ends. Secondly, dephosphorylation of vector could confirm that most of 
the transformants (92.8% for ligations with BamH I site
13
, 77% for blunt-end ligations, 93% for ligations with 
different clone sites, and 100% for ligations with Xba I site, respectively) were with recombinants. Thirdly, 
optimization of the amount and ratio of the inserts and vectors could increase the rate of monomeric, 
correct-oriented recombinants (47% ± 31%, 93% ± 12%, 36% ± 10% and 51.3% ± 15.2%
13
, respectively). 
Finally, Top10 cells could significantly improve the transformation efficiencies, and therefore facilitate to 
obtain enough colonies for identification
13
. We designated our optimized method as a “Combinatorial 
Strategy”. With our Strategy, most vectors could be successfully constructed through “one ligation, one 
transformation, and three to five minipreps”. This study provided important quantitative models for efficiently 
cloning different kinds of vectors with various clone sites, therefore, radically accelerated the biology and 
medicine research on gene functions both in vivo and in vitro. 
 
Materials and Methods 
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Design of SDM primers 
 
SDM was performed to insert Pst I sites for plasmids pcDNA4/β5WT and pcDNA4/β5T1A (Invitrogen, Lab 
stock) at the 3’-end of β5WT and β5T1A open reading frames, respectively, to create pcDNA4/β5WT/3’-Pst 
I, and pcDNA4/β5T1A/3’-Pst I vectors. In addition, Xba I sites were inserted by SDM at the 5’ and 3’ ends 
of β5T1A open reading frame to create pcDNA4/β5T1A/5’-Xba I/3’-Xba I with pcDNA4/β5T1A as template. 
All primers, including Pst I and Xba I insertions, were designed according to the guide of Stratagene’s 
QuickChange
TM
 SDM kit, synthesized and purified by Integrated DNA Technologies. For all primers, 
mutagenized positions were denoted in lower case and underlined. 
pcDNA4/3’-Pst I insertion forward: 
5’-CATCACCATTGAGTTTAAACctgcagCCGCTGATCAGCCTCGACTG-3’; 
pcDNA4/3’-Pst I insertion complement: 
5’-CAGTCGAGGCTGATCAGCGGctgcagGTTTAAACTCAATGGTGATG-3’; 
pcDNA4/5’-Xba I insertion forward: 5’-GAATTCTGCAtctagaGATATCCAGC-3’; 
pcDNA4/5’-Xba I insertion complement: 5’-GCTGGATATCtctagaTGCAGAATTC-3’; 
pcDNA4/3’-Xba I insertion forward: 5’-CCATTGAGTTTAAACtctagaCCGCTGATCAGCCTC-3’; 
pcDNA4/3’-Xba I insertion complement: 5’-GAGGCTGATCAGCGGtctagaGTTTAAACTCAATGG-3’; 
The melting temperatures (Tm, primer-to-template annealing temperature) were calculated by Online 
Software “Calculate a primer’s melting temperature for the QuickChange Site-Directed Mutagenesis Kit” 
created by David Kim (http://depts.washington.edu/bakerpg/primertemp.html), and primer-pair 
self-annealing temperatures (Tm
*
) were calculated by Integrated DNA Technologies SciTools OligoAnalyzer 
3.1 (http://www.idtdna.com/analyzer/applications/oligoanalyzer/default.aspx), respectively (Table 1). All the 
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DNA preparation kits, including Miniprep, Maxiprep, and Gel extraction kits, were purchased from QIAGEN. 
The DNA purities used in experiments were tested by NanoDrop-1000 Spectrophotometer (NanoDrop 
Technologies), and all the A260/280 values were ≥ 1.80. 
 
Mutagenesis 
 
The PCR amplifications were carried out with GeneAmp® PCR System 2700 (AB Applied Biosystems). The 
50µl PCR reactions were carried out with 50ng templates, 125ng of each forward and complement primers, 
20µM of each dNTP, 2.5U of PfuUltra DNA polymerase in 1×reaction buffer (Statagene). The thermal cycler 
program for amplifications was as follows: denaturation at 94°C for 2 min; 18 cycles at 94°C for 30 sec, 
annealing for 30 sec, at 60°C for pcDNA4/β5WT/3’-Pst I and pcDNA4/β5T1A/3’-Pst I insertions, 53°C for 
pcDNA4/β5WT/5’-Xba I and pcDNA4/β5T1A/5’-Xba I insertions, and 58°C for pcDNA4/β5T1A/5’-Xba 
I/3’-Xba I insertion, respectively (Table 2, Figure 2 and 3), and at 72°C for 7 min; followed by a final 
extension at 72°C for 10 min. When the amplifications were finished, 1µl (10U) of Dpn I (Statagene) was 
added into each reaction, and incubated at 37°C for 1 hour. Finally, 1µl reaction products were used for 
transformation into 50µl DH5α or Top10 competent cells (Invitrogen), respectively, according to the 
manufacturer’s guides. All the transformants were used to spread plates. Transformation colonies were 
selected and their plasmids were isolated by miniprep, and the positive mutants were identified by sequencing. 
All the primers are available upon request.   
 
Preparation of vector and insert DNA 
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LVs, pWPI/Neo (Addgene plasmid 12254, modified by replacing EGFP sequence with Neo, a kind gift from 
Robert Strome)
13
 was digested with Swa I (NEW ENGLAND BioLabs), pLenti CMV/TO Puro DEST 
(Addgene plasmid 17293)
27
 was digested with EcoR V (NEW ENGLAND BioLabs), respectively. and 
pLVCT-tTR-KRAB (Addgene plasmid 11643)
9
 was digested with Pme I and Pst I (NEW ENGLAND 
BioLabs), sequentially. In addition, pTetO-HGMoPrP (a kind gift from Dr. Prusiner, University of California, 
San Francisco)
12
 was digested with Xba I (NEW ENGLAND BioLabs), and pcDNA4/β5T1A/5’-Xba 
I/3’-Xba I was digested with Not I and Xho I, simultaneously (NEW ENGLAND BioLabs) (Figure 1, 2 and 
3; Table 3). All the digested vectors were treated with CIP (NEW ENGLAND BioLabs) at 37°C water bath 
for 1 hour, respectively, to remove the 5’-phosphate groups18. And then, all the vectors were purified by 1% 
agarose gel electrophoresis to remove CIP, and recovered by QIAGEN Gel Extraction Kit
13
. 
 
α-synuclein (Syn) WT and A30P, A53T mutants were cut off from pcNA6 with Pme I, and Rab3A WT, 
T36N, Q81L mutants, and GDI WT R218E, R240A mutants were cut off from pcDNA3.1 with Pme I 
(Figure 1). The different DNA fragments of β5 WT and T1A mutant were cut off from pcDNA4 with EcoR 
V and Pme I, EcoR V and Pst I, Not I and Xho I, and Xba I, respectively, for different cloning (Figure 1, 2 
and 3). Particularly, when β5WT and β5T1A mutant were severed from pcDNA4/3’-Pst I vectors with 
5’-EcoR V and 3’-Pst I enzymes, at first, the vectors needed to be digested by EcoR V enzyme, and then with 
Pst I enzyme, sequentially (Figure 2, Table 3). Because, there were a Pst I site at 952 nucleotide and a EcoR 
V site at 955 nucleotide. As a general rule, when the vectors and inserts were prepared with enzyme digestion, 
try to avoid using restriction enzymes that cleave within 12bp of each other in the multiple cloning site, or, 
after one of these sites has been cleaved, the second site will be located too close to the end of the linear 
DNA to allow efficient cleavage by the second enzyme
18
. All the vectors described above were from lab 
stocks. Then, all the inserts, α-Syn, Rab3A, GDI, and β5, both WT and mutants were recovered by 1% 
agarose electrophoresis and gel extraction procedure, respectively. 
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. 
Ligation 
 
The ligation reactions were set up according to the molar ratios of inserts and vectors, and DNA amounts, 
indicated in Table 3. In 10µl ligation systems, the vector and insert were pooled together, warmed at 45°C for 
5 min to melt any cohesive termini that have re-annealed during fragment preparation, then chilled on ice for 
2 min, and then 1µl 10×T4 DNA ligase buffer and 0.5µl high-concentration T4 DNA ligase (400U/µl or 
2000U/µl, NEW ENGLAND BioLabs) were added
18
. The 10µl reaction mixtures were incubated in 
GeneAmp® PCR System 2700 at 16°C for 16 hours followed by inactivation at 65°C for 10 min, and then set 
at 4°C until transformation. 
 
Transformation and identification 
 
2µl (about 30~80ng) volumes of the ligation products were used to transform 50µl Top10 competent cells 
according to the manufacturer’s instructions (Table 3). In order to obtain more colonies, all the 
transformation cells were used to spread plates. Positive colonies were primarily analyzed by restriction 
endonuclease digestion, and further confirmed by DNA sequencing. 
 
Data statistics 
Data were analyzed by Mean ± SD and Student’s t-Test. 
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Figure legends 
 
 
Figure 1 Schematic representation for the cloning of pWPI and pLenti LVs 
a. α-Syn WT and A30P, A53T mutants were cleaved from pcDNA6 with Pme I restriction endonuclease. 
Rab3A WT and T36N, Q81L mutants, and GDI WT and R218E, R240A mutants, were also digested with 
Pme I enzyme from pcDNA3.1. β5 WT and T1A mutant were cleaved from pcDNA4 with 5’-EcoR V 
and 3’-Pme I enzymes. The pWPI vector was digested with Swa I enzyme, followed by CIP treatment. 
EcoR V, Pme I and Swa I were blunt-end cleavage endonuclease enzymes, therefore, the inserts could be 
ligated into the pWPI vector. 
b. Inducible vector pLenti (pLenti CMV/TO Puro DEST) was digested with EcoR V enzyme, and followed 
by CIP treatment, and then the inserts β5 WT and T1A were ligated with pLenti to clone the inducible 
LV pLenti/β5WT and pLenti/β5T1A. 
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
do
i:1
0.
10
38
/n
pr
e.
20
12
.6
96
5.
1 
: P
os
te
d 
3 
M
ar
 2
01
2
 19 
 
Figure 2 Schematic representation for the cloning of pLVCT inducible LVs 
The EGFP fragment could be cut off by a 5’-Pme I and a 3’-Pst I clone sites in the original pLVCT 
(pLVCT-tTR-KRAB) vector. To clone pLVCT/β5WT and pLVCT/β5T1A inducible vectors, a Pst I clone 
site was inserted at the 3’-end of β5 WT and T1A mutant taken pcDNA4/β5WT and pcDNA4/β5T1A 
plasmids as templates by SDM. Then the inserts were, at first, cleaved from pcDNA4 by EcoR V, and then 
by Pst I, sequentially. The pLVCT vector was treated with CIP following Pme I and Pst I digestion, and the 
EGFP fragment was replaced by β5 WT and T1A mutant, respectively. N
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Figure 3 Schematic representation for the cloning of inducible pTet/β5WT and 
pTet/β5T1A vectors 
Two Xba I sites were sequentially inserted at the 5’, and 3’-ends of β5T1A, taken pcDNA4/β5T1A plasmid 
as template, by SDM to form pcDNA4/β5T1A/5’-Xba I/3’-Xba I. pcDNA4/β5WT plasmid was digested by 
Not I and Xho I, simultaneously, to recover 5'-Not I-β5WT-3’-Xho I fragment. At the same time, 
pcDNA4/β5T1A/5’-Xba I/3’-Xba I plasmid was digested with Not I and Xho I, followed by the treatment 
with CIP, to recover dephosphorylated Not I-pcDNA4/5’-Xba I/3’-Xba I-Xho I vector fragment. And then, 
the insert and vector were ligated together to construct pcDNA4/β5WT/5’-Xba I/3’-Xba I vector. Finally, 
both of them were digested with Xba I to recover 5’-Xba I-β5WT/T1A-3’-Xba I inserts, and the pTet original 
vector was also cleaved by Xba I, followed by CIP treatment, to construct pTet/β5WTand pTet/β5T1A 
inducible expression vectors using Xba I clone site. 
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Figure 4 Comparison of the cloning efficiencies with various clone sites 
The percentages of inserted colonies and positive colonies between Blunt sites/Different sites, Blunt 
sites/Xba I site, Different sites/Xba I site were analyzed by Mean ± SD and Student’s t-Test. The percentages 
of inserted clones with ligation of blunt-end sites, different clone sites, and a Xba I site, were approximately 
77% ± 25% (n=13), 93% ± 12% (n=3), and 100% ± 0 (n=2) of identified clones, respectively. Among them, 
the efficiencies between blunt sites and Xba I site were significantly different (P=0.0064<0.05). Whereas, 
the differences between blunt sites/different sites and different sites/Xba I site were not significantly different 
(P=0.1304 vs P=0.4226, P>0.05). On the other hand, the percentages of positive clones with ligation of 
blunt-end sites, different clone sites, and a Xba I site, were approximately 47% ± 31% (n=13), 93% ± 12% 
(n=3), and 36% ± 10% (n=2), respectively. Among them, the efficiencies between blunt sites/Xba I site and 
different sites/Xba I site were not significantly different (P=0.3468 vs P=0.0154, P>0.05). In contrast, the 
efficiencies between blunt sites/different sites cloning were significantly different (P=0.0018<0.05). 
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Tables 
 
Table 1 Characteristics of mutagenesis primer pairs 
Primer name Length/mutation (bases) Tm (°C) Tm* (°C) 
pcDNA4/3’-Pst I insertion forward 46/6 75.2 69.1 
pcDNA4/3’-Pst I insertion complement 46/6 75.2 69.1 
pcDNA4/5’-Xba I insertion forward 26/6 49.8 54.9 
pcDNA4/5’-Xba I insertion complement 26/6 49.8 54.9 
pcDNA4/3’-Xba I insertion forward 36/6 65.4 63.3 
pcDNA4/3’-Xba I insertion complement 36/6 65.4 63.3 
Note: Tm: primer-to-template annealing temperature, which considered the mismatches of the bases; Tm
*
: 
primer-pair self-annealing temperatures.  
 
Table 2 Mutagenesis efficiency of Pst I and Xba I insertion 
Mutagenesis (insertion) Annealing temperature (°C) Hosts Transformed colonies Sequenced colonies Positive colonies 
pcDNA4/β5WT/3’-Pst I 60 Top10 4 (n=1) 2 1 (50%) 
pcDNA4/β5T1A/3’-Pst I 60 DH5α 5 (n=1) 3 1 (33.3%) 
pcDNA4/β5WT/5’-Xba I* 53 Top10 ~50 (n=3) 18 0  
pcDNA4/β5T1A/5’-Xba I 53 Top10 16 (n=1) 10 1 (10%) 
pcDNA4/β5T1A/5’-Xba I/3’-Xba I 58 Top10 8 (n=1) 8 4 (50%) 
* Note: One PCR mutagenesis reaction was run, and three transformations were performed. 
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Table 3 Construction efficiencies of different vectors with various clone sites 
Vector sizes (kb) & clone 
sites (5’-, 3’-) 
Insert sizes (kb) & clone sites 
(5’-, 3-‘) 
Inserts/vectors, DNA 
concentration (ng/µl) 
Transformed 
colonies 
Identified 
colonies 
Inserted 
colonies 
Positive 
colonies 
Data analyses 
(Mean ± SD) 
pWPI (11.4, Swa I) α-Syn-WT (0.64, Pme I)  2 : 1 (39.2) 13 (n=1) 4 (n=1) 3 (75%) 1 (25%) 47% ± 31% 
pWPI (11.4, Swa I) α-Syn-A30P (0.64, Pme I) 1.8 : 1 (38.8) 7 (n=1) 4 (n=1) 4 (100%) 3 (75%)  
pWPI (11.4, Swa I) α-Syn-A53T (0.64, Pme I) 3.4 : 1 (41.9) 10 (n=1) 4 (n=1) 1 (25%) 1 (25%)  
pWPI (11.4, Swa I) Rab3A-WT (0.78, Pme I) 3.2 : 1 (20.3) 2 (n=1) 2 (n=1) 2 (100%) 2 (100%)  
pWPI (11.4, Swa I) Rab3A-T36N (0.78, Pme I) 3.5 : 1 (20.7) 14 (n=1) 10 (n=1) 8 (80%) 2 (20%)  
pWPI (11.4, Swa I) Rab3A-Q81L (0.78, Pme I) 1.9 : 1 (18.9) 11 (n=1) 4 (n=1) 4 (100%) 3 (75%)  
pWPI (11.4, Swa I) GDI-WT (1.44, Pme I) 1.7 : 1 (26.2) 13 (n=1) 6 (n=1) 4 (66.7%) 3 (50%)  
pWPI (11.4, Swa I) GDI-R218E (1.44, Pme I) 1.8 : 1 (24.5) 7 (n=1) 5 (n=1) 2 (40%) 1 (20%)  
pWPI (11.4, Swa I) GDI-R240A (1.44, Pme I) 2.4 : 1 (28.0) 10 (n=1) 4 (n=1) 4 (100%) 1 (25%)  
pWPI (11.4, Swa I) β5-WT (0.9, EcoR V, Pme I) 2.1 : 1 (23.3) 20 (n=1) 2 (n=1) 2 (100%) 2 (100%)  
pWPI (11.4, Swa I) β5-T1A (0.9, EcoR V, Pme I) 1.7 : 1 (19.5) 2 (n=1) 2 (n=1) 1 (50%) 1 (50%)  
pLenti (7.9, EcoR V) β5-WT (0.9, EcoR V, Pme I) 22 : 1 (18.9) 12 (n=1) 8 (n=1) 6 (75%) 3 (37.5%)  
pLenti (7.9, EcoR V) β5-T1A (0.9, EcoR V, Pme I) 14.1 : 1 (14.0) 13 (n=1) 8 (n=1) 7 (87.5%) 1 (12.5%)  
pLVCT (12, Pme I, Pst I) β5-WT (0.9, EcoR V, Pst I) 3 : 1 (17.6) ~300 (n=1) 5 (n=1) 4 (80%) 4 (80%) 93% ± 12% 
pLVCT (12, Pme I, Pst I) β5-T1A (0.9, EcoR V, Pst I) 3 : 1 (17.6) ~100 (n=1) 5 (n=1) 5 (100%) 5 (100%)  
pcDNA4 (5.1, Not I, Xho I) β5-WT (0.8, Not I, Xho I) 1.9 : 1 (28.1) ~500 (n=1) 8 (n=1) 8 (100%) 8 (100%)  
pTet (3.2, Xba I) β5-WT (0.9, Xba I) 2.1 : 1 (21.9) ~1000 (n=1) 14 (n=1) 14 (100%) 4 (28.6%) 36% ± 10% 
pTet (3.2, Xba I) β5-T1A (0.9, Xba I) 1.5 : 1 (19.7) ~1000 (n=1) 14 (n=1) 14 (100%) 6 (42.9%)  
Notes: Percentages of positive colonies between: 
Blunt sites/different sites: P=0.0018; Blunt sites/Xba I: P=0.3468; Different sites/Xba I: P=0.0154. 
Percentages of inserted colonies between: 
Blunt sites/Different sites: P=0.1304; Blunt sites/Xba I: P=0.0064; Different sites/Xba I: P=0.4226. 
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